NCT Number: NCT07802561
The goal of this randomized clinical trial is to compare metformin and glyburide for controlling blood sugar in pregnant women with gestational diabetes mellitus (GDM) who require treatment with oral medication.
The main question the study aims to answer is:
Q: Is treatment failure less common with metformin or glyburide in pregnant women with GDM?
The study will include 92 pregnant women aged 18-45 years with a singleton pregnancy, diagnosed with GDM between 13 and 33 weeks of pregnancy and requiring medication to control blood sugar. Participants will be randomly assigned to one of two treatment groups.
Participants in the metformin group will receive metformin, starting at 850 mg once daily and increased to a maximum of 2,550 mg per day according to their blood sugar levels.
Participants in the glyburide group will receive glyburide, starting at 2.5 mg twice daily and increased according to their blood sugar levels, up to a maximum of 20 mg per day.
Blood glucose levels will be monitored regularly using a glucometer. Treatment will be considered successful when at least 80% of the recorded blood glucose measurements are within the target range. Treatment failure will be defined as fewer than 80% of blood glucose measurements being within the target range after up to 4 weeks of treatment. Participants who have treatment failure or cannot continue the assigned medication because of adverse effects will be switched to insulin therapy.
Participants will be followed during pregnancy until delivery. The study will record treatment failure as the primary outcome and will also assess maternal outcomes, including preeclampsia, polyhydramnios, and preterm delivery, as well as newborn outcomes including macrosomia and the need for admission to a neonatal intensive care unit (NICU).
The study will determine whether metformin or glyburide provides better blood sugar control and reduces the need to switch to insulin in pregnant women with gestational diabetes.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Phase 4
Multan, Punjab Province, 60000, Pakistan
Location status: Recruiting
Iqra M Principal Investigator, MBBS
CONTACT
Iqra M Principal Investigator, MBBS
PRINCIPAL_INVESTIGATOR
Saima A Professor, FCPS
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Starting dose for Metformin will be 850 mg once daily after a meal and/or at 10:00 p.m. The dose will be increased to twice or three times daily according to weekly blood glucose measurements, up to a maximum of 2,550 mg/day. Treatment will continue until delivery.
Other names: Glucophage
Starting dose of glyburide will be 2.5 mg twice daily, 30 minutes before meals and/or at 10:00 p.m. The dose will be increased according to weekly blood glucose measurements, up to a maximum of 20 mg/day. Treatment will continue until delivery.
Time frame: From initiation of oral treatment, up to four weeks
Treatment failure will be defined as fewer than 80% of combined weekly blood glucose measurements being within the target range after treatment initiation. Target glucose levels are pre-prandial <95 mg/dL and post-prandial <140 mg/dL. Participants with treatment failure will be switched to insulin therapy.
Time frame: From enrollment in the study up to delivery (till 42 weeks of gestation)
Incidence of polyhydramnios based on an amniotic fluid index >24 ± 2 cm measured by obstetric ultrasonography.
Time frame: From enrollment in the study up to delivery of the fetus (till 42 weeks of gestation)
Incidence of delivery occurring before 37 completed weeks of gestation.
Time frame: At delivery, with newborn birth weight assessed immediately after birth within three hours
Incidence of newborn birth weight greater than 4,000 grams.
Time frame: From birth through discharge from birth hospitalization, up to 48 hours
Number and proportion of newborn requiring admission to the neonatal intensive care unit according to institutional criteria
Contact information is provided by the study sponsor or research team.
Iqra M Principal Investigator, MBBS
CONTACT
Saima A Professor, FCPS
CONTACT
Nishtar Medical University
Other
Comparison of Metformin Versus Glyburide in the Control of Gestational Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06858787
Diabetes Mellitus, Diabetes, Gestational
New York, United States
View Trial DetailsNCT06896799
Diabetes Mellitus, Diabetes, Gestational
Belfast, United Kingdom
View Trial DetailsNCT07470320
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oxford, United Kingdom
View Trial DetailsNCT07717424
Diabetes Mellitus, Diabetes, Gestational
Ludhiana, Punjab, India
View Trial Details